Kiromic Biopharma

Personalized CAR T Treatment

Procel 2 efforts Clin0 oncology; Isocel 2 efforts Clin0 oncology

Kiromic Biopharma is addressing solid tumors through the development of allogeneic gamma delta T-cell therapies. To develop these therapies Kiromic is using Diamond AI, a neural network of predictive analytics and machine learning synergistically designed to identify the best possible cancer therapy targets. This enables Kiromic to screen for new cancer targets from billions of data points, streamlining their approach to develop effective CAR-T therapies. In addition, Kiromic is lowering manufacturing costs through development of ABBIE, their non-viral, genetic engineering platform to offer a more precise approach to deliver their therapeutic proteins.